Recent Alerts
How to trade in a Down Market and Win Big
Hot Stocks to Watch, Thursday 08-18-2011
We suggest Members hold on to yesterday's Two Picks; EK and CLWR.
CMRG - Casual Male Retail Group, operates as a specialty retailer of men?s apparel in the United States, Canada, and Europe. It operates its stores under the Casual Male XL, Casual Male XL Outlets, Destination XL, Rochester Clothing, B & T Factory Direct, Shoes XL, and Living XL trade names. Attractive.
Get Alerts that MakeMoney!® Everything else:HOTair©
Bulls chasing Bears to the hills, Stocks to Watch 08-11-2011
EK- Eastman Kodak Company provides imaging technology products and services to the photographic and graphic communications markets worldwide. It operates in three segments: Consumer Digital Imaging Group (CDG); Film, Photofinishing, and Entertainment Group (FPEG); and Graphic Communications Group (GCG). Very Attractive, Huge Patent portfolio is on the block, short and medium term play.
MOTR - Motricity, enables mobile operators, brands, and advertising agencies to maximize the reach and economic potential of the mobile ecosystem through the delivery of relevance-driven merchandising, marketing, and advertising solutions. It leverages predictive analytics capabilities to deliver the right content, to the right person at the right time. Very Attractive, bouncing back.
Get Alerts that MakeMoney!® Everything else:HOTair©
Hot Stock Picks for Thursday 07-28-2011, NEI, CTIC
NEI - Network Engines, provides application platforms and appliance solutions for original equipment manufacturers and independent software vendors worldwide. It designs and manufactures application platforms and appliance solutions on which software applications are applied for enterprise and telephony information technology networks. Very Attractive.
CTIC - Cell Therapeutics, a biopharmaceutical company is developing Pixuvri, a novel anthracycline derivative for the treatment of non-Hodgkins lymphoma, as well as for various other hematologic malignancies and solid tumors; OPAXIO, a Phase III clinical trial product for the treatment of ovarian, brain, esophageal, and non-small cell lung cancer; and Brostallicin, a phase II trial for the treatment of metastatic triple-negative breast cancer. Very Attractive, Bouncing back from 52WK Lows.
Get Alerts that MakeMoney!® Everything else:HOTair©
Don't miss this Biotech stock
Hot Stock Picks for Wednesday 07-27-2011
MYRX - Myriad Pharmaceuticals, a biotechnology company is developing small molecule drugs for the treatment of cancer. The company?s product pipeline includes clinical and pre-clinical product candidates with mechanisms of action and novel chemical structures.
Its product candidates in clinical development include Azixa (MPC-6827), which is under Phase II clinical trial for the treatment of metastatic melanoma. In addition the company has a strong pipe line of drugs under development. Very Attractive, must be on your list.
Get Alerts that MakeMoney!® Everything else:HOTair©
Feed Entries
